|
Hep C and Fatty Liver Disease Linked by Enzyme
Pittsburgh researchers have found that an enzyme known to participate in fat production is elevated in those with Hepatitis C. Further exploration of this enzyme could help physicians better predict which HCV patients are at risk of developing fatty liver...
ANA773 Resumes Race Against Hepatitis C
By reducing the dosing schedule in half, Anadys Pharmaceuticals returns to their investigation of ANA773, a Toll-Like Receptor-7 agonist prodrug. Approaching the Hepatitis C virus differently from most other contenders, Phase I clinical trials evaluating the safety, tolerability and viral-load...
Popular Illegal Drug Extra Harmful with HCV
Although scores of Americans are turning to the street drug methamphetamine to keep them awake and thin, scientists have found that it worsens Hepatitis C infection in two worrisome ways....
|
|
|
Effects of Propranolol on the Hepatic Hemodynamic Response to Physical Exercise
in Patients With Cirrhosis
| table 3. Systemic Hemodynamics in Baseline
Conditions, After Placebo or Propranolol Administration, During Exercise
and 30 Minutes After Recovery Period |
|
|
Placebo or Propranolol Infusion
|
| Baseline |
Pre-exercise |
Exercise |
Recovery |
ANOVA |
|
HR (beats · min 1) |
| Placebo |
81 ± 5 |
78 ± 5 |
119 ± 5*,.gif) |
84 ± 5 |
0.000 |
| Propranolol |
83 ± 2 |
66 ± 1* |
100 ± 2*, |
72 ± 2* |
0.000 |
| MAP (mm Hg) |
| Placebo |
99 ± 4 |
96 ± 4 |
126 ± 11*, |
95 ± 4 |
0.003 |
| Propranolol |
100 ± 4 |
98 ± 4 |
113 ± 4*, |
90 ± 6* |
0.01 |
CO (L · min1) |
|
|
|
| Placebo |
9.9 ± 0.8 |
9.7 ± 1.0 |
17.6 ± 0.5*, |
9.0 ± 2.0 |
0.004 |
| Propranolol |
8.2 ± 0.6 |
6.2 ± 0.5* |
11.1 ± 0.8*, |
5.9 ± 0.5* |
0.000 |
| SV (mL) |
| Placebo |
105 ± 8 |
103 ± 9 |
148 ± 6*, |
90 ± 7 |
0.03 |
| Propranolol |
98 ± 8 |
93 ± 8 |
110 ± 7 |
81 ± 6 |
ns |
| SVR (dyn · s · cm5) |
| Placebo |
842 ± 113 |
807 ± 106 |
464 ± 51*, |
887 ± 298 |
0.05 |
| Propranolol |
1,022 ± 96 |
1,329 ± 139 |
770 ± 83*, |
1,215 ± 161 |
0.02 |
| PAP (mm Hg) |
| Placebo |
13.0 ± 2.3 |
12.3 ± 2.7 |
27.5 ± 6.1*, |
10.0 ± 2.0 |
0.05 |
| Propranolol |
13.6 ± 1.2 |
16.5 ± 1.4 |
38.7 ± 2.8*, |
14.1 ± 1.7 |
0.000 |
| PCP (mm Hg) |
|
|
|
| Placebo |
6.7 ± 1.2 |
6.0 ± 2.6 |
18.8 ± 5.1*, |
3.3 ± 0.3 |
0.05 |
| Propranolol |
7.6 ± 0.5 |
11.4 ± 0.8 |
30.0 ± 2.4*, |
7.9 ± 1.0 |
0.000 |
| RAP (mm Hg) |
| Placebo |
3.2 ± 0.8 |
3.7 ± 1.4 |
8.2 ± 2.0 |
6.3 ± 3.3 |
ns |
| Propranolol |
4.7 ± 0.7 |
6.6 ± 0.9 |
16.4 ± 2.6*, < |
7.5 ± 2.6* |
0.001 |
| PVR (dyn · s · cm5) |
| Placebo |
52 ± 6 |
55 ± 8 |
40 ± 9 |
67 ± 31 |
ns |
| Propranolol |
59 ± 9 |
67 ± 11 |
72 ± 15 |
84 ± 11 |
ns |
|
NOTE. Data are shown as means ± SEM.
Abbreviations: SV, stroke volume; SVR, systemic vascular resistance;
PAP, mean pulmonary artery pressure; PCP, wedged pulmonary capillary
pressure; RAP, right atrial pressure; PVR, pulmonary vascular resistance;
ns, not significant.
* P < .05 vs.
baseline.
P < .05 vs.
pre-exercise.
Measured in 5 patients
in placebo group and in 6 patients in propranolol group. |
|
Return To Article
|
|
